Cargando…

Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Durussel, Jérôme, Daskalaki, Evangelia, Anderson, Martin, Chatterji, Tushar, Wondimu, Diresibachew H., Padmanabhan, Neal, Patel, Rajan K., McClure, John D., Pitsiladis, Yannis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571963/
https://www.ncbi.nlm.nih.gov/pubmed/23418527
http://dx.doi.org/10.1371/journal.pone.0056151
Descripción
Sumario:Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. METHODS: 19 trained men received rHuEpo injections of 50 IU•kg(−1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. [Image: see text] O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study. RESULTS: Relative to baseline, running performance significantly improved by ∼6% after administration (10∶30±1∶07 min:sec vs. 11∶08±1∶15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10∶46±1∶13 min:sec, p<0.001), while [Image: see text] O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(−1)•kg(−1) vs. 56.0±6.2 mL•min(−1)•kg(−1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(−1)•kg(−1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(−1) vs. 12.7±1.2 g•kg(−1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (−0.53 g•kg(−1)•wk(−1), 95% confidence interval (CI) (−0.68, −0.38) vs. 0.54 g•kg(−1•)wk(−1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(−1), p<0.001). CONCLUSION: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated [Image: see text] O(2 max) and Hb(mass).